Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23

Hardman & Co Research on Tissue Regenix (TRX):

Continuation of the positive momentum

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 1H’23 results highlighted the benefits and efficiencies being derived from investment and reorganisation in manufacturing capacity, with the first underlying EBITDA-positive reporting period. With further strong growth forecast in 2H’23, TRX is on the cusp of achieving profitability. Phase 2 of its capacity expansion programme is expected to be completed in 2025.

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/continuation-of-the-positive-momentum/

If you are interested in meeting the company, you can register your interest by clicking on the above link

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.